According to Pluo Pharmaceutical's announcement, it achieved operating revenue of 6.835 billion yuan in the first three quarters, a year-on-year decrease of 11.97%; net profit attributable to shareholders of listed companies was 614 million yuan, a year-on-year decrease of 12.37%. Revenue for the third quarter was 2,011 billion yuan, down 13.28% year on year; net profit attributable to shareholders of listed companies was 91.2934 million yuan, down 33.47% year on year. The company's Q3 net profit was 901 million and Q2 net profit was 273 million. Based on this calculation, Q3 net profit decreased 66% month-on-month.

According to Pluo Pharmaceutical's announcement, it achieved operating revenue of 6.835 billion yuan in the first three quarters, a year-on-year decrease of 11.97%; net profit attributable to shareholders of listed companies was 614 million yuan, a year-on-year decrease of 12.37%. Revenue for the third quarter was 2,011 billion yuan, down 13.28% year on year; net profit attributable to shareholders of listed companies was 91.2934 million yuan, down 33.47% year on year. The company's Q3 net profit was 901 million and Q2 net profit was 273 million. Based on this calculation, Q3 net profit decreased 66% month-on-month.